Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies*. (August 2014)

• Record Type: Journal Article
• Authors: Ralla, Bernhard; Stephan, Carsten; Meller, Sebastian; Dietrich, Dimo; Kristiansen, Glen; Jung, Klaus
• Is Part Of: Critical reviews in clinical laboratory sciences. Volume 51:Number 4(2014:Jul./Aug.)
• Page Start: 200
• Page End: 231
• Publication Date: 2014-08
• Subjects: Diagnosis, laboratory -- Periodicals; Medicine, Clinical -- Periodicals; 616.07
• DOI: 10.3109/10408363.2014.914888
• Languages: English
• ISSNs: 1040-8363

Abstract

<abstract> <title>Abstract</title> <p>This review focuses on the promising potential of nucleic acids in body fluids such as blood and urine as diagnostic, prognostic, predictive and monitoring biomarkers in urologic malignancies. The tremendous progress in the basic knowledge of molecular processes in cancer, as shown in the companion review on nucleic acid-based biomarkers in tissue of urologic tumors, provides a strong rationale for using these molecular changes as non-invasive markers in body fluids. The changes observed in body fluids are an integrative result, reflecting both tissue changes and processes occurring in the body fluids. The availability of sensitive methods has only recently made possible detailed studies of DNA- and RNA-based markers in body fluids. In addition to these biological aspects, methodological aspects of the determination of nucleic acids in body fluids, i.e. pre-analytical, analytical and post-analytical issues, are particularly emphasized. The characteristic changes of RNA (differential mRNA and miRNA expression) and DNA (concentrations, integrity index, mutations, microsatellite and methylation alterations) in serum/plasma and urine samples of patients suffering from the essential urologic cancers of the prostate, bladder, kidney and testis are summarized and critically discussed below. To translate the promising results into clinical practice, laboratory scientists and clinicians have to collaborate to resolve the challenges of harmonized and feasible pre-analytical and analytical conditions for the selected markers and to validate these markers in well-designed and sufficiently powered multi-center studies.</p> </abstract>